Origins of zinc starvation in Mycobacterium tuberculosis during chronic infection

结核分枝杆菌慢性感染期间锌饥饿的起源

基本信息

  • 批准号:
    10286274
  • 负责人:
  • 金额:
    $ 22.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-08 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Summary Tuberculosis (TB) is a major public health burden in the world: over a million people die of the disease every year and an estimated one third of the world’s population harbor the pathogen Mycobacterium tuberculosis (Mtb). Treatment of TB requires 6 to 9 months of an antibiotic regimen comprising of multiple antibiotics. Difficulties in treatment of TB are largely attributed to non-inheritable drug resistance in the pathogen that are considered to be developed due to unique microenvironments in the host (e.g. nutrient depletion, hypoxia and antibiotic exposure). Recently, we uncovered one such condition: zinc starvation. In response to zinc starvation both Mycobacterium smegmatis and Mycobacterium tuberculosis induce ribosome remodeling and ribosome hibernation. Ribosome remodeling involves replacement of multiple ribosomal (r-) proteins containing the zinc-binding CXXC motif (therefore called C+ r-proteins) by their motif- free C- paralogues. Ribosome hibernation involves binding of mycobacterial protein Y (Mpy) to the decoding center of the C- ribosome. Ribosome remodeling occurs at a zinc concentration that permits growth, whereas ribosome hibernation occurs at a growth-restrictive concentration of zinc. Moreover, mycobacterial cells harboring remodeled and hibernating ribosomes are resistant to aminoglycosides and spectinamides. Furthermore, we demonstrated that zinc in the host lung environment during chronic Mtb infection is low enough to induce ribosome remodeling and Mpy- dependent resistance to streptomycin, an aminoglycoside used in the treatment of multi-drug resistant TB. However, the underlying cause for zinc starvation in Mtb during chronic infection is not known. Based on the idea that metal ion starvation during bacterial infections is an innate host defense strategy, called nutritional immunity, we propose to identify the components of host immune system responsible for zinc starvation in Mtb (Aim 1), and determine the potential of zinc oxide nanoparticles as an adjunct therapeutic (Aim 2). Upon completion of the project we will gain further insight into the cause of zinc starvation and related ribosome remodeling/hibernation in Mtb during chronic infection, and develop a therapeutic strategy to minimize the drug resistance caused by these changes to the ribosome in Mtb.
摘要 结核病(TB)是世界上主要的公共卫生负担:超过100万人死于 每年都有疾病,据估计,世界上三分之一的人口携带这种病原体 结核分枝杆菌(Mtb)结核病的治疗需要6至9个月的抗生素 由多种抗生素组成的养生法。结核病的治疗困难很大程度上归因于 病原体中不可遗传的耐药性,被认为是由于独特的 宿主的微环境(例如,营养耗竭、缺氧和抗生素暴露)。最近, 我们发现了一种这样的情况:锌缺乏。为了应对锌饥饿, 耻垢分枝杆菌和结核分枝杆菌诱导核糖体重塑和 核糖体冬眠。核糖体重塑涉及多个核糖体(r-)的替换 含有锌结合CXXC基序的蛋白质(因此称为C+r-蛋白质) 免费的C-副词。核糖体冬眠涉及分枝杆菌蛋白Y(Mpy)与 C-核糖体的解码中心。核糖体重塑发生在锌浓度达到 允许生长,而核糖体冬眠发生在限制生长的锌浓度。 此外,含有重塑和冬眠核糖体的分枝杆菌细胞对 氨基糖苷类和壮观酰胺类药物。此外,我们还证明了宿主肺中的锌 慢性结核分枝杆菌感染期间的环境低到足以诱导核糖体重塑和Mpy- 链霉素是一种治疗多药耐药的氨基糖苷类药物,对链霉素具有依赖性耐药 耐药结核病。然而,结核分枝杆菌在慢性感染期间锌饥饿的根本原因是 不知道。基于细菌感染时金属离子饥饿是一种先天宿主的观点 防御策略,称为营养免疫,我们建议识别宿主的成分 结核分枝杆菌锌饥饿的免疫系统(目标1),并确定锌的潜力 氧化物纳米颗粒作为辅助治疗(目标2)。项目完成后,我们将获得 锌饥饿及相关核糖体重塑/冬眠原因的进一步研究 慢性感染期间的结核分枝杆菌,并制定治疗策略,将耐药性降至最低 由结核分枝杆菌核糖体的这些变化引起。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anil Kumar Ojha其他文献

Anil Kumar Ojha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anil Kumar Ojha', 18)}}的其他基金

Origins of zinc starvation in Mycobacterium tuberculosis during chronic infection
结核分枝杆菌慢性感染期间锌饥饿的起源
  • 批准号:
    10425433
  • 财政年份:
    2021
  • 资助金额:
    $ 22.37万
  • 项目类别:
Alternative ribosomes and antibiotic tolerance in mycobacteria.
分枝杆菌中的替代核糖体和抗生素耐受性。
  • 批准号:
    10165472
  • 财政年份:
    2017
  • 资助金额:
    $ 22.37万
  • 项目类别:
Alternative ribosomes and antibiotic tolerance in mycobacteria.
分枝杆菌中的替代核糖体和抗生素耐受性。
  • 批准号:
    9916712
  • 财政年份:
    2017
  • 资助金额:
    $ 22.37万
  • 项目类别:
Enzyme-based lysis of mycobacteria
基于酶的分枝杆菌裂解
  • 批准号:
    8698490
  • 财政年份:
    2014
  • 资助金额:
    $ 22.37万
  • 项目类别:
Identification of factors that control Mycobacterium tuberculosis biofilm growth
控制结核分枝杆菌生物膜生长的因素的鉴定
  • 批准号:
    8147487
  • 财政年份:
    2010
  • 资助金额:
    $ 22.37万
  • 项目类别:
Identification of factors that control Mycobacterium tuberculosis biofilm growth
控制结核分枝杆菌生物膜生长的因素的鉴定
  • 批准号:
    7687400
  • 财政年份:
    2008
  • 资助金额:
    $ 22.37万
  • 项目类别:
Identification of factors that control Mycobacterium tuberculosis biofilm growth
控制结核分枝杆菌生物膜生长的因素的鉴定
  • 批准号:
    7508820
  • 财政年份:
    2008
  • 资助金额:
    $ 22.37万
  • 项目类别:

相似海外基金

Ototoxicity of modified aminoglycosides
修饰氨基糖苷类药物的耳毒性
  • 批准号:
    10663352
  • 财政年份:
    2022
  • 资助金额:
    $ 22.37万
  • 项目类别:
Ototoxicity of modified aminoglycosides
修饰氨基糖苷类药物的耳毒性
  • 批准号:
    10552427
  • 财政年份:
    2022
  • 资助金额:
    $ 22.37万
  • 项目类别:
Aminoglycosides with reduced ototoxicity
具有降低耳毒性的氨基糖苷类
  • 批准号:
    10156973
  • 财政年份:
    2020
  • 资助金额:
    $ 22.37万
  • 项目类别:
Aminoglycosides with reduced ototoxicity
具有降低耳毒性的氨基糖苷类
  • 批准号:
    10377538
  • 财政年份:
    2020
  • 资助金额:
    $ 22.37万
  • 项目类别:
Aminoglycosides with reduced ototoxicity via miRNA targeting
通过 miRNA 靶向降低耳毒性的氨基糖苷类药物
  • 批准号:
    9891947
  • 财政年份:
    2019
  • 资助金额:
    $ 22.37万
  • 项目类别:
Aminoglycosides with reduced ototoxicity via miRNA targeting
通过 miRNA 靶向降低耳毒性的氨基糖苷类药物
  • 批准号:
    9982540
  • 财政年份:
    2019
  • 资助金额:
    $ 22.37万
  • 项目类别:
Antibacterial properties of amphiphilic aminoglycosides
两亲性氨基糖苷类药物的抗菌特性
  • 批准号:
    524825-2018
  • 财政年份:
    2018
  • 资助金额:
    $ 22.37万
  • 项目类别:
    University Undergraduate Student Research Awards
Nanobiocapteurs de résonance des plasmons de surface pour les aminoglycosides
氨基糖苷类表面等离激元共振的纳米生物捕获剂
  • 批准号:
    495915-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 22.37万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Aminoglycosides with reduced ototoxicity
降低耳毒性的氨基糖苷类
  • 批准号:
    9197240
  • 财政年份:
    2016
  • 资助金额:
    $ 22.37万
  • 项目类别:
Designing new aminoglycosides to alleviate inner ear toxicity
设计新的氨基糖苷类药物以减轻内耳毒性
  • 批准号:
    8943277
  • 财政年份:
    2015
  • 资助金额:
    $ 22.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了